Vericel Corp chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.39
Dividend & YieldN/A$ (N/A)
Beta 1.99
Market capitalization 1B
Operating cash flow 21.26M
ESG Scores unknown

Company description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 899k -1.02M 33k 1.49M
Total Cashflows From Investing Activities -67.03M 10.62M -17.16M -3.5M
Net Borrowings -17.53M
Total Cash From Financing Activities 58.86M 5.26M 6.44M 9.17M
Change To Operating Activities 18k -1.66M -1.53M -687k
Issuance Of Stock 77.11M 5.29M 6.63M 11.18M
Net Income -8.14M -9.66M 2.86M -7.47M
Change In Cash -8.58M 8.69M 6.85M 34.71M
Effect Of Exchange Rate
Total Cash From Operating Activities -412k -7.18M 17.57M 29.04M
Depreciation 1.43M 1.74M 2.38M 2.96M
Change To Account Receivables -5.18M -8.71M -2.34M -2.93M
Other Cashflows From Financing Activities -710k -26k -28k -348k
Change To Netincome 10.33M 15.4M 18.7M 39.7M
Capital Expenditures -2.68M -2.62M -2.63M -7.92M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 13.6M 30.39M 13.02M 16.29M
Income Before Tax -8.14M -9.66M 3.04M -7.58M
Net Income -8.14M -9.66M 2.86M -7.47M
Selling General Administrative 49.01M 61.14M 68.84M 97.59M
Gross Profit 58.7M 80.28M 84.23M 106.03M
Ebit -3.91M -11.25M 2.37M -7.85M
Operating Income -3.91M -11.25M 2.37M -7.85M
Interest Expense -1.73M -8k -6k -4k
Income Tax Expense 180k -111k
Total Revenue 90.86M 117.85M 124.18M 156.18M
Cost Of Revenue 32.16M 37.57M 39.95M 50.16M
Total Other Income ExpenseNet -4.23M 1.59M 672k 272k
Net Income From Continuing Ops -8.14M -9.66M 2.86M -7.47M
Net Income Applicable To Common Shares -8.14M -9.66M 2.86M -7.47M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 16.46M 42.15M 71.35M 73.24M
Total Stockholder Equity 102.23M 111.09M 134.26M 170.46M
Other Current Liabilities 713k
Total Assets 118.69M 153.24M 205.61M 243.71M
Common Stock 471.18M 489.75M 510.06M 553.9M
Other Current Assets 2.85M 2.95M 3.89M 4.25M
Retained Earnings -369.01M -378.68M -375.81M -383.29M
Treasury Stock 65k 21k 14k -154k
Cash 18.29M 26.89M 33.62M 68.33M
Total Current Liabilities 14.79M 19.8M 22.48M 26.05M
Other Stockholder Equity 65k 21k 14k -154k
Property, Plant, and Equipment 5.91M 32.25M 57.74M 59.03M
Total Current Assets 112.78M 111.66M 123.56M 158.46M
Net Tangible Assets 102.23M 111.09M 134.26M 170.46M
Net Receivables 23.45M 32.17M 34.5M 37.44M
Accounts Payable 7.11M 6.34M 6.75M 9.02M


Insider Transactions

Here are the insider transactions of stock shares related to Vericel Corp:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SIEGAL JONATHANSale at price 25.47 per share.D2022-10-14Officer331
SIEGAL JONATHAND2022-09-30Officer937
WRIGHT LISAD2022-06-01Director433
GILMAN STEVEN CSale at price 30.94 per share.D2022-04-29Director900
MCLAUGHLIN KEVIN FD2022-04-27Director2.6k
RUBINO ALAN LD2022-04-27Director2.6k
WOTTON PAUL KD2022-04-27Director2.6k
ZERBE ROBERT LD2022-04-27Director2.6k
GILMAN STEVEN CD2022-04-27Director2.6k
HAGEN HEIDID2022-04-27Director2.6k
WRIGHT LISAD2022-04-27Director2.35k
HOPPER JONATHAN MARKSale at price 41.41 - 41.46 per share.D2022-03-01Officer16.74k
HOPPER JONATHAN MARKConversion of Exercise of derivative security at price 10.95 - 18.00 per share.D2022-03-01Officer20k
HOPPER JONATHAN MARKD2022-02-18Officer1.75k
HALPIN MICHAELD2022-02-18Chief Operating Officer2.81k
COLANGELO DOMINICK CD2022-02-18Chief Executive Officer8.94k
FLYNN SEAN CD2022-02-18General Counsel1.75k
HOPPER JONATHAN MARKD2022-02-11Officer1.62k
HALPIN MICHAELD2022-02-11Chief Operating Officer3.5k
COLANGELO DOMINICK CD2022-02-11Chief Executive Officer7.5k
COLANGELO DOMINICK CD2022-02-04Chief Executive Officer6.94k
HOPPER JONATHAN MARKD2022-02-04Officer650
HALPIN MICHAELD2022-02-04Chief Operating Officer1.88k
MARA JOSEPH ANTHONY JRD2021-12-31Chief Financial Officer4k
HOPPER JONATHAN MARKSale at price 40.00 - 40.14 per share.D2021-12-22Officer15.88k
HOPPER JONATHAN MARKConversion of Exercise of derivative security at price 10.95 - 16.66 per share.D2021-12-22Officer20k
GILMAN STEVEN CSale at price 39.17 per share.D2021-11-29Director5k
GILMAN STEVEN CConversion of Exercise of derivative security at price 3.74 per share.D2021-11-29Director5k
GILMAN STEVEN CSale at price 50.57 per share.D2021-10-27Director5k
GILMAN STEVEN CConversion of Exercise of derivative security at price 3.74 per share.D2021-10-27Director5k
HALPIN MICHAELSale at price 50.57 per share.D2021-10-26Chief Operating Officer10k
HALPIN MICHAELConversion of Exercise of derivative security at price 2.65 per share.D2021-10-26Chief Operating Officer10k
GILMAN STEVEN CSale at price 48.85 per share.D2021-09-30Director5k
GILMAN STEVEN CConversion of Exercise of derivative security at price 3.74 per share.D2021-09-30Director5k
FLYNN SEAN CStock Award(Grant) at price 41.48 per share.D2021-09-30General Counsel145
MARA JOSEPH ANTHONY JRD2021-09-30Chief Financial Officer4k
FLYNN SEAN CSale at price 55.11 per share.D2021-08-27General Counsel7.2k
FLYNN SEAN CConversion of Exercise of derivative security at price 16.25 per share.D2021-08-27General Counsel7.2k
HALPIN MICHAELSale at price 48.03 per share.D2021-08-16Chief Operating Officer15k
HALPIN MICHAELConversion of Exercise of derivative security at price 2.65 per share.D2021-08-16Chief Operating Officer15k
FLYNN SEAN CSale at price 55.01 per share.D2021-07-21General Counsel2.8k
FLYNN SEAN CConversion of Exercise of derivative security at price 16.25 per share.D2021-07-21General Counsel2.8k
FLYNN SEAN CSale at price 51.18 per share.D2021-07-15General Counsel10k
FLYNN SEAN CConversion of Exercise of derivative security at price 16.25 per share.D2021-07-15General Counsel10k
HALPIN MICHAELSale at price 53.54 per share.D2021-07-12Chief Operating Officer20k
HALPIN MICHAELConversion of Exercise of derivative security at price 2.65 per share.D2021-07-12Chief Operating Officer20k
HOPPER JONATHAN MARKSale at price 57.14 per share.D2021-06-30Officer134
HOPPER JONATHAN MARKConversion of Exercise of derivative security at price 10.95 per share.D2021-06-30Officer694
MARA JOSEPH ANTHONY JRD2021-06-30Chief Financial Officer4k
HAGEN HEIDIConversion of Exercise of derivative security at price 4.12 - 6.00 per share.D2021-05-19Director6.75k
WOTTON PAUL KSale at price 50.52 per share.D2021-05-14Director5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Vericel Corp. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Vericel Corp

Here is the result of two systematic investment strategies applied to Vericel Corp. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Vericel Corp

The following chart shows the equity curve of the two systematic investment strategies applied to Vericel Corp:

Vericel Corp automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 208.79% on the backtest period.

Performance at glance

Performance

208.79 %

Latent gain

4690.63 $

Invested capital

2246.57 $

Annualized return

50.43 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Vericel Corp

This is the result of two momentum investment strategies applied to Vericel Corp. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Vericel Corp

The following chart shows all the entries opened by the momentum investment system on Vericel Corp:

Vericel Corp momentum entries
  • The first momentum investment strategy would give 205.32% of return on Vericel Corp. That represents 8271.41$ of latent gain with 4028.59$ of employed capital.
  • The second momentum investment strategy would give 229.04% of return on Vericel Corp. That represents 6267.28$ of latent gain with 2736.32$ of employed capital.
Performance at glance (1Q Momentum)

Performance

205.32 %

Latent gain

8271.41 $

Invested capital

4028.59 $

Annualized return

97.76 %
Performance at glance (2Q Momentum)

Performance

229.04 %

Latent gain

6267.28 $

Invested capital

2736.32 $

Annualized return

62.58 %

Momentum equity curve on Vericel Corp

The following chart shows the equity curve of the two momentum strategies applied to Vericel Corp:

Vericel Corp momentum equity

Note: the dividends potentially given by Vericel Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Vericel Corp

The following chart shows the employed capital evolution of the two momentum strategies on Vericel Corp since the beginning:

Vericel Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Vericel Corp

Buy the dip entry openings on Vericel Corp

Vericel Corp

The performance achieved by the robo-advisor on Vericel Corp is 209.21%. That represents 1031.95$ of latent gain with 493.25$ of employed capital. The following chart shows Vericel Corp stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Vericel Corp, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

209.21 %

Latent gain

1031.95 $

Invested capital

493.25 $

Annualized return

97.76 %

Equity curve of the strategy applied to Vericel Corp

The following chart shows the result of the investment strategy applied to Vericel Corp:

Vericel Corp

Note: the dividends potentially given by Vericel Corp are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Vericel Corp

The following chart shows the employed capital evolution since the beginning of the investment strategy on Vericel Corp:

Vericel Corp

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Vericel Corp

In this section, I will compare the three previous investment strategies applied to Vericel Corp.

Equity curve comparison on Vericel Corp

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Vericel Corp investment strategy comparison

Employed capital comparison on Vericel Corp

Vericel Corp investment comparison

Performance comparison on Vericel Corp

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 208.79% 4690.63$ 2246.57$ 50.43%
Momentum 1 quarter 205.32% 8271.41$ 4028.59$ 52.65%
Momentum 2 quarters 229.04% 6267.28$ 2736.32$ 62.58%
Non-directional 209.21% 1031.95$ 493.25$ 97.76%
Annualized return comparison

Automatic investment

50.43 %

Momentum 1Q

62.58 %

Momentum 2Q

62.58 %

Non-directional

97.76 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Vericel Corp:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • POLLUX PROP

  • Note: The algorithm computes the probability of correlation between Vericel Corp and the other stocks. There may be false positives or some missing correlated stocks. If the price of Vericel Corp does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Vericel Corp
    Country United States
    City Cambridge
    Address 64 Sidney Street
    Phone 617 588 5555
    Website vcel.com
    FullTime employees 281
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VCEL
    Market www.nasdaq.com

    Vericel Corp ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown